FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation

被引：6

作者：

Blackmon, Amanda ^{[1
]}

Aldoss, Ibrahim ^{[1
]}

Ball, Brian J. ^{[1
,2
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Dept Hematol & HCT, Div Leukemia, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY | 2022年 / 12卷

关键词：

FLT3; inhibitor; posttransplantation; maintenance; stem -cell transplantation; midostaurin; sorafenib; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; MINIMAL RESIDUAL DISEASE; TYROSINE KINASE INHIBITORS; ACUTE MYELOGENOUS LEUKEMIA; PHASE-I; PROGNOSTIC-SIGNIFICANCE; SORAFENIB MAINTENANCE; ALLELIC RATIO; AML;

D O I：

10.2147/BLCTT.S281252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mutations in the FLT3 gene are associated with poor prognosis in patients with AML, even after consolidation with allogeneic hematopoietic cell transplantation (alloHCT) in first remission. Treatment failure in FLT3-mutated AML is largely driven by excessive risk of relapse compared to other genetic subtypes, including in patients post-alloHCT. As a result, there is substantial interest in studying posttransplant maintenance therapy in FLT3-mutated AML as an approach to optimize disease control and improve long-term outcomes. Clinical trials utilizing posttransplant FLT3 inhibitors, such as sorafenib and midostaurin, have shown feasibility, safety, and encouraging posttransplant outcomes, and there are ongoing studies using newer-generation tyrosine-kinase inhibitors as posttransplant maintenance therapy. Here, we review the toxicities and efficacy of FLT3 inhibitors as posttransplant maintenance, recommendations on the use of FLT3 inhibitors by international consensus guidelines, and highlight key remaining questions.

引用

页码：137 / 147

页数：11

共 74 条

[61] Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia [J].

Smith, BD ;

Levis, M ;

Beran, M ;

Giles, F ;

Kantarjian, H ;

Berg, K ;

Murphy, KM ;

Dauses, T ;

Allebach, J ;

Small, D .

BLOOD, 2004, 103 (10) :3669-3676

[62] Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis [J].

Smith, Catherine C. ;

Paguirigan, Amy ;

Jeschke, Grace R. ;

Lin, Kimberly C. ;

Massi, Evan ;

Tarver, Theodore ;

Chin, Chen-Shan ;

Asthana, Saurabh ;

Olshen, Adam ;

Travers, Kevin J. ;

Wang, Susana ;

Levis, Mark J. ;

Perl, Alexander E. ;

Radich, Jerald P. ;

Shah, Neil P. .

BLOOD, 2017, 130 (01) :48-58

[63] Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia [J].

Smith, Catherine C. ;

Wang, Qi ;

Chin, Chen-Shan ;

Salerno, Sara ;

Damon, Lauren E. ;

Levis, Mark J. ;

Perl, Alexander E. ;

Travers, Kevin J. ;

Wang, Susana ;

Hunt, Jeremy P. ;

Zarrinkar, Patrick P. ;

Schadt, Eric E. ;

Kasarskis, Andrew ;

Kuriyan, John ;

Shah, Neil P. .

NATURE, 2012, 485 (7397) :260-U153

[64] Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia [J].

Stirewalt, DL ;

Kopecky, KJ ;

Meshinchi, S ;

Engel, JH ;

Pogosova-Agadjanyan, EL ;

Linsley, J ;

Slovak, ML ;

Willman, CL ;

Radich, JP .

BLOOD, 2006, 107 (09) :3724-3726

[65] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation [J].

Stone, R. M. ;

Mandrekar, S. J. ;

Sanford, B. L. ;

Laumann, K. ;

Geyer, S. ;

Bloomfield, C. D. ;

Thiede, C. ;

Prior, T. W. ;

Doehner, K. ;

Marcucci, G. ;

Lo-Coco, F. ;

Klisovic, R. B. ;

Wei, A. ;

Sierra, J. ;

Sanz, M. A. ;

Brandwein, J. M. ;

de Witte, T. ;

Niederwieser, D. ;

Appelbaum, F. R. ;

Medeiros, B. C. ;

Tallman, M. S. ;

Krauter, J. ;

Schlenk, R. F. ;

Ganser, A. ;

Serve, H. ;

Ehninger, G. ;

Amadori, S. ;

Larson, R. A. ;

Doehner, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (05) :454-464

[66] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 [J].

Stone, RM ;

DeAngelo, DJ ;

Klimek, V ;

Galinsky, I ;

Estey, E ;

Nimer, SD ;

Grandin, W ;

Lebwohl, D ;

Wang, YF ;

Cohen, P ;

Fox, EA ;

Neuberg, D ;

Clark, J ;

Gilliland, DG ;

Griffin, JD .

BLOOD, 2005, 105 (01) :54-60

[67] Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis [J].

Thiede, C ;

Steudel, C ;

Mohr, B ;

Schaich, M ;

Schäkel, U ;

Platzbecker, U ;

Wermke, M ;

Bornhäuser, M ;

Ritter, M ;

Neubauer, A ;

Ehninger, G ;

Illmer, T .

BLOOD, 2002, 99 (12) :4326-4335

[68] Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission [J].

Tien, Feng-Ming ;

Tsai, Cheng-Hong ;

Huang, Sheng-Chuan ;

Liu, Jia-Hau ;

Chen, Chien-Yuan ;

Kuo, Yuan-Yeh ;

Chuang, Yi-Kuang ;

Tseng, Mei-Hsuan ;

Peng, Yen-Ling ;

Liu, Ming-Chih ;

Liu, Chia-Wen ;

Liao, Xiu-Wen ;

Lin, Liang-In ;

Wu, Yu-Sin ;

Hou, Mei-Fang ;

Wu, Shang-Ju ;

Hsu, Szu-Chun ;

Ko, Bor-Sheng ;

Chou, Wen-Chien ;

Yao, Ming ;

Hou, Hsin-An ;

Tang, Jih-Luh ;

Tien, Hwei-Fang .

BONE MARROW TRANSPLANTATION, 2022, 57 (01) :95-105

[69] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].

Wilhelm, SM ;

Carter, C ;

Tang, LY ;

Wilkie, D ;

McNabola, A ;

Rong, H ;

Chen, C ;

Zhang, XM ;

Vincent, P ;

McHugh, M ;

Cao, YC ;

Shujath, J ;

Gawlak, S ;

Eveleigh, D ;

Rowley, B ;

Liu, L ;

Adnane, L ;

Lynch, M ;

Auclair, D ;

Taylor, I ;

Gedrich, R ;

Voznesensky, A ;

Riedl, B ;

Post, LE ;

Bollag, G ;

Trail, PA .

CANCER RESEARCH, 2004, 64 (19) :7099-7109

[70] Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry [J].

Wodicka, Lisa M. ;

Ciceri, Pietro ;

Davis, Mindy I. ;

Hunt, Jeremy P. ;

Floyd, Mark ;

Salerno, Sara ;

Hua, Xuequn H. ;

Ford, Julia M. ;

Armstrong, Robert C. ;

Zarrinkar, Patrick P. ;

Treiber, Daniel K. .

CHEMISTRY & BIOLOGY, 2010, 17 (11) :1241-1249

← 1 2 3 4 5 6 7 8 →